Premium
Prognostic value of the pretreatment serum level of cytokeratin fraction 21‐1 in undifferentiated nasopharyngeal carcinoma: A study of 332 cases
Author(s) -
Wei Zhengbo,
Zeng Xianjie,
Xu Jian,
Duan Xuwei,
Yang Jianbo,
Xie Ying
Publication year - 2014
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23261
Subject(s) - nasopharyngeal carcinoma , medicine , cytokeratin , gastroenterology , biomarker , oncology , multivariate analysis , stage (stratigraphy) , carcinoma , immunohistochemistry , radiation therapy , biology , paleontology , biochemistry
Background Prognostic value of serum cytokeratin fraction 21‐1 (CYFRA 21‐1) has not been fully validated for nasopharyngeal carcinoma (NPC). Methods Serum CYFRA 21‐1 levels of 332 patients with NPC were measured before treatment, and their association with overall survival (OS), tumor‐free survival (TFS), time to local recurrence (TLR), and time to distant recurrence (TDR) was studied. Results Pretreatment serum CYFRA 21‐1 level of patients with classification of T 1+2 , N 0 , stage I+II was significantly lower than that of those with T 3+4 , N 1+2+3 and III+IV, respectively. Multivariate analysis showed that a high pretreatment serum level of CYFRA 21‐1 and T classification were independent predictors of poor OS and TDR. A high pretreatment level of CYFRA 21‐1 was an independent predictor of shorter TFS and TLR. Conclusion The pretreatment serum level of CYFRA 21‐1 would be a reliable biomarker to evaluate the long‐term prognosis of patients with undifferentiated NPC. © 2013 Wiley Periodicals, Inc. Head Neck 36 : 71–76, 2014